Skip to Content

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Allosteric MEK Inhibition

Allomek Therapeutics presents pharmacokinetic data and an excellent in vivo efficacy in pharmacology model at the AACR National meeting, 2011, Orlando, Florida

Allomek Therapeutics is a privately held pharmaceutical company committed to helping cancer patients by the discovery and development of targeted therapies. Allomek’s primary interest lies in the inhibition of targets associated with the Ras pathway. Allomek has discovered a novel class of MEK kinase inhibitors that improve the biopharmaceutical properties of previous MEK inhibitors. Allomek’s clinical candidate, CIP-1374, is an allosteric MEK kinase inhibitor that combines potent activity against MEK1/2 kinase and against chemo-resistant ovarian cancer stem cells.